Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Catalent Inc    CTLT


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Catalent : The Effect of Pipeline Success to be Presented at SCOPE Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
02/12/2019 | 08:55am EDT

SOMERSET, N.J. - February 12, 2019 - Catalent Pharma Solutions, a global leader in clinical supply services, today announced that Eva Allen, Senior Clinical Supplies Manager, will present at the upcoming 10th Annual SCOPE Summit for Clinical Ops Executives at the Hyatt Regency Orlando Hotel, Orlando, Florida, on Feb. 18-21, 2019.

In her presentation, 'Turning Up the Heat: The Effect of Pipeline Success on Clinical Supplies' on Tuesday, Feb. 19 at 3:40 p.m., Ms. Allen will discuss the ways in which clinical supply strategy and execution change as sponsors progress into later phase trials. Her presentation will explore the aspects of clinical supply that sponsors find most challenging, and the primary concerns associated with outsourcing clinical supplies. She will also discuss clinical supply considerations for studies conducted outside of North America.

In her role at Catalent, Ms. Allen is responsible for end-to-end clinical supply strategy, forecasting, and support, including interactive response technology (IRT) set up and inventory management. She has 18 years' experience in the pharmaceutical industry, focusing on commercial and clinical manufacturing supplies management. Ms. Allen holds a bachelor's degree in industrial distribution and logistics from East Carolina University.

For more information visit this page.

To arrange a meeting with Ms. Allen at the conference, contact Ed Dutton at NEPR - edward@nepr.eu

Media Contacts:

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0)161 728 5880

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™


Catalent Inc. published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2019 13:54:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CATALENT INC
08:40aCATALENT : Collaborates with MGB Biopharma to Provide Accelerated Formulation an..
04:34aCATALENT : invests US$14 million in softgel encapsulation
04/25CATALENT : invests $14M to expand manufacturing at its facility in Germany
04/25CATALENT : Collaborates with MGB Biopharma
04/25CATALENT : Technologies to Improve Patient Adherence and Trends in Pharmaceutica..
04/24CATALENT : Technologies to Improve Patient Adherence and to be Discussed at CPhI..
04/24CATALENT : Invests $14 Million at its Eberbach, Germany Softgel Facility
04/24CATALENT : Invests $14 Million at its Eberbach, Germany Softgel Facility; Expand..
04/23CATALENT : Invests $14 Million at its Eberbach, Germany Softgel Facility
04/19CATALENT : Paragon to Build Second GMP Mfg. Facility
More news
Financials ($)
Sales 2019 2 541 M
EBIT 2019 429 M
Net income 2019 162 M
Debt 2019 1 890 M
Yield 2019 -
P/E ratio 2019 44,32
P/E ratio 2020 33,42
EV / Sales 2019 3,29x
EV / Sales 2020 2,89x
Capitalization 6 473 M
Duration : Period :
Catalent Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT INC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 49,6 $
Spread / Average Target 12%
EPS Revisions
John R. Chiminski Chairman, President & Chief Executive Officer
Alessandro Maselli Senior Vice President-Global Operations
Wetteny Joseph CFO, Principal Accounting Officer & Senior VP
Jack L. Stahl Lead Independent Director
Rolf Allan Classon Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT INC43.14%6 473
JOHNSON & JOHNSON7.87%371 856
ROCHE HOLDING LTD.8.67%223 303
PFIZER-9.26%219 907
NOVARTIS10.35%204 940
MERCK AND COMPANY-0.09%197 192